ACORN CAPITAL ADVISORS, LLC
Regulatory profile
From Form ADV, the SEC filer profile, 13D/13G type codes and N-CEN, never from the name.
Portfolio style
Measured from the filed 13F common-share book for Jun 30, 2026, never from the firm's own description.
Closest benchmark: the Russell 2000 as of 2026-06-30, active share 99.6%; sector active share 90.9% against the combined 13F book's sector weights.
Over time 7 measured quarters
How the bands are measured
Style bands measure the filed 13F common-share book each closed quarter, tested in this order. Unknown: under $10,000,000 of valued equity or 5 stocks. Index-like (100+ stocks): active share of 20% or less against the closest benchmark, which is the S&P 500, S&P MidCap 400, S&P SmallCap 600, Russell 1000, Russell 2000, Nasdaq-100 or Dow Jones Industrial Average (weighted by an index-tracking fund's reported holdings or the index's constituents nearest the quarter end, over the names resolved to companies, and only when those are 90%+ of its weight) or every 13F filer's combined book, or index series holding 80%+ of the registered fund assets it advises (N-CEN) and equal to 50%+ of its book. Systematic-like: 500+ stocks, 100%+ annual turnover and a top 10 weight of 25% or less. Concentrated: a top 10 weight of 60%+ or 12 or fewer effective positions. Diversified active: none of these. Turnover is the smaller of buys and sells over average equity value, summed over four quarters: low under 30%, high 100%+. Horizon is the value-weighted number of quarters each position has been held: short under 4, long 12+.
Clone Performance
Build a hypothetical price-return history from this filer's public 13F holdings.
View clone backtestPortfolio Concentration
20 tracked positions · as of Jun 30, 2026 · Δ vs Mar 31, 2026Portfolio Trend
Sector Breakdown
As of Jun 30, 2026| Sector | % Portfolio | Value |
|---|---|---|
| Healthcare | 100.0% | $366,458,500 |
Last Quarter's Activity
Export CSVAdded To
Positions the filer increased| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| KPTI | Karyopharm Therapeutics Inc. | +1,230,287 | 1,518,113 | $14,831,964 | |
| AURA | Aura Biosciences, Inc. | +333,333 | 929,077 | $6,596,446 | |
| JBIO | Jade Biosciences, Inc. | +200,000 | 986,760 | $21,925,807 | |
| JSPR | Jasper Therapeutics, Inc. | +26,667 | 1,438,159 | $605,464 | |
| CGON | CG Oncology, Inc. | +999 | 1,131,500 | $80,393,075 | |
| No positions match the current search. | |||||
New Positions
Positions the filer opened this quarter| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| ENGN | enGene Therapeutics Inc. | 1,271,257 | $2,199,274 | |
| No positions match the current search. | ||||
| Ticker | Company | Type | Shares | Value (USD) | % of Portfolio | History |
|---|---|---|---|---|---|---|
| CGON |
CG Oncology, Inc.
Healthcare
|
Added | 1,131,500 | $80,393,075 | 21.94% | |
| URGN |
UroGen Pharma Ltd.
Healthcare
|
Held | 1,673,420 | $61,581,856 | 16.80% | |
| TRVI |
Trevi Therapeutics, Inc.
Healthcare
|
Held | 2,144,844 | $40,001,340 | 10.92% | |
| CADL |
Candel Therapeutics, Inc.
Healthcare
|
Held | 3,497,948 | $36,028,864 | 9.83% | |
| PBYI |
Puma Biotechnology, Inc.
Healthcare
|
Held | 4,131,299 | $33,504,834 | 9.14% | |
| JBIO |
Jade Biosciences, Inc.
Healthcare
|
Added | 986,760 | $21,925,807 | 5.98% | |
| BCAX |
Bicara Therapeutics Inc.
Healthcare
|
Reduced | 643,381 | $19,101,981 | 5.21% | |
| KPTI |
Karyopharm Therapeutics Inc.
Healthcare
|
Added | 1,518,113 | $14,831,964 | 4.05% | |
| OKUR |
OnKure Therapeutics, Inc.
Healthcare
|
Held | 2,839,674 | $12,948,913 | 3.53% | |
| HELP |
Helus Pharma Inc.
Healthcare
|
Held | 1,540,266 | $10,181,158 | 2.78% | |
| TARA |
Protara Therapeutics, Inc.
Healthcare
|
Held | 1,752,115 | $6,693,079 | 1.83% | |
| AURA |
Aura Biosciences, Inc.
Healthcare
|
Added | 929,077 | $6,596,446 | 1.80% | |
| LONA |
LeonaBio, Inc.
Healthcare
|
Held | 634,539 | $5,831,413 | 1.59% | |
| VSTM |
Verastem, Inc.
Healthcare
|
Held | 1,469,153 | $5,612,164 | 1.53% | |
| WHWK |
Whitehawk Therapeutics, Inc.
Healthcare
|
Held | 1,139,363 | $5,218,282 | 1.42% | |
| QTTB |
Q32 Bio Inc.
Healthcare
|
Reduced | 216,171 | $2,754,018 | 0.75% | |
| ENGN |
enGene Therapeutics Inc.
Healthcare
|
NEW | 1,271,257 | $2,199,274 | 0.60% | |
| JSPR |
Jasper Therapeutics, Inc.
Healthcare
|
Added | 1,438,159 | $605,464 | 0.17% | |
| BCAB |
BioAtla, Inc.
Healthcare
|
Reduced | 108,126 | $447,641 | 0.12% | |
| YARW |
Yarrow Bioscience, Inc.
Healthcare
|
Held | 1,425 | $927 | 0.00% |
Covers the securities this platform tracks: U.S.-listed common stock and the put/call positions reported on it. A 13F can also report security types outside that coverage — preferred shares, bonds, warrants, untracked share classes — so the filing's own declared total can exceed the figures above. The source filing is linked at the top of this table.